[go: up one dir, main page]

WO2000047721A3 - Methods of inducing insulin positive progenitor cells - Google Patents

Methods of inducing insulin positive progenitor cells Download PDF

Info

Publication number
WO2000047721A3
WO2000047721A3 PCT/US2000/003422 US0003422W WO0047721A3 WO 2000047721 A3 WO2000047721 A3 WO 2000047721A3 US 0003422 W US0003422 W US 0003422W WO 0047721 A3 WO0047721 A3 WO 0047721A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
progenitor cells
insulin positive
inducing insulin
positive progenitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/003422
Other languages
French (fr)
Other versions
WO2000047721A2 (en
Inventor
David Kagan
Kevin Pang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ontogeny Inc
Original Assignee
Ontogeny Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ontogeny Inc filed Critical Ontogeny Inc
Priority to AU32270/00A priority Critical patent/AU3227000A/en
Publication of WO2000047721A2 publication Critical patent/WO2000047721A2/en
Publication of WO2000047721A3 publication Critical patent/WO2000047721A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/645—Secretins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to methods for modulating the growth state of cells using secretin therapeutics and antagonists. The methods can be used as therapies for diseases caused by, or coincident with, aberrant glucose metabolism, such as Type II Diabetes Mellitus.
PCT/US2000/003422 1999-02-10 2000-02-10 Methods of inducing insulin positive progenitor cells Ceased WO2000047721A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU32270/00A AU3227000A (en) 1999-02-10 2000-02-10 Methods of inducing insulin positive progenitor cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11957599P 1999-02-10 1999-02-10
US60/119,575 1999-02-10

Publications (2)

Publication Number Publication Date
WO2000047721A2 WO2000047721A2 (en) 2000-08-17
WO2000047721A3 true WO2000047721A3 (en) 2001-01-25

Family

ID=22385139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/003422 Ceased WO2000047721A2 (en) 1999-02-10 2000-02-10 Methods of inducing insulin positive progenitor cells

Country Status (2)

Country Link
AU (1) AU3227000A (en)
WO (1) WO2000047721A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025306A1 (en) * 2000-01-07 2002-02-28 Baetge Edward E. Methods of increasing the glucose responsiveness of pancreatic ss-cells
US6759039B2 (en) 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
GB2399823B (en) 2001-12-07 2006-02-15 Geron Corp Islet cells from primate pluripotent stem cells
IL162132A0 (en) 2001-12-07 2005-11-20 Geron Corp Chondrocyte precursors derived from human embryonic stem cells
US7101546B2 (en) 2001-12-21 2006-09-05 Amcyte, Inc. In situ maturation of cultured pancreatic stem cells having a specified, intermediate stage of development
US20040115226A1 (en) * 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
WO2007149182A2 (en) 2006-06-19 2007-12-27 Geron Corporation Differentiation and enrichment of islet-like cells from human pluripotent stem cells
US20130023491A1 (en) * 2009-12-18 2013-01-24 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265884A (en) * 1978-09-28 1981-05-05 Nordisk Insulinlaboratorium Therapeutically active polypeptides or acid addition salts thereof and a process for producing such compounds
US4533494A (en) * 1982-02-15 1985-08-06 Eisai Co., Ltd. Process for purifying secretin
JPH06133731A (en) * 1992-10-23 1994-05-17 Zenetsukusu Kk Diet food

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265884A (en) * 1978-09-28 1981-05-05 Nordisk Insulinlaboratorium Therapeutically active polypeptides or acid addition salts thereof and a process for producing such compounds
US4533494A (en) * 1982-02-15 1985-08-06 Eisai Co., Ltd. Process for purifying secretin
JPH06133731A (en) * 1992-10-23 1994-05-17 Zenetsukusu Kk Diet food

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FUNAKOSHI A. ET AL: "Changes in Insulin Secretion after Secretin Administration and the Implications in Diabetes Mellitus", ENDOCRINOLOGICA JAPONOCA, vol. 32, 1985, pages 473 - 479, XP000909684 *
KOFOD H. ET AL: "Secretin and its C-terminal Hexapeptide Potentiates Insulin release in Mouse Islets", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 250, 1986, pages E107 - E113, XP000916519 *
LERNER R.L. ET AL: "Augmentation by Secretin of Glucose Stimulated Insulin Responses in Diabetic Subjects", CLINICAL RESEARCH, vol. 25, 1977, pages 126A, XP000916521 *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 433 (C - 1237) 12 August 1994 (1994-08-12) *

Also Published As

Publication number Publication date
WO2000047721A2 (en) 2000-08-17
AU3227000A (en) 2000-08-29

Similar Documents

Publication Publication Date Title
HK1045267A1 (en) Methods and reagents for treating glucose metabolic disorders
MY117785A (en) New 3-aryl-2-hydroxypropionic acid derivatives i
WO2006105501A3 (en) Control of blood glucose in diabetes treatment using pulmonarily administered insulin in combination with basal insulin
WO2000078333A3 (en) Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
AU2369595A (en) In vitro growth of functional islets of langerhans and in vivo uses thereof
WO2005012485A3 (en) Methods for treating diabetes and related disorders using pde10a inhibitors
HK1049841A1 (en) Novel bisamidate phosphonate prodrugs
WO2006103429A3 (en) High affinity hiv t cell receptors
WO2006000567A3 (en) Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function
IL179740A0 (en) Non-integrative and non-replicative lentivirus, preparation and uses thereof
NO20002038L (en) Insoluble insulin compositions
WO2008124522A3 (en) Amylin formulations
PL346520A1 (en) Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
MX2007007174A (en) Cycloalkylamine derivatives.
WO2006088576A3 (en) Polypeptide formulations and methods for making, using and characterizing them
WO2001019542A8 (en) Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions
WO2006079641A3 (en) Insulin derivatives conjugated with structurally well defined branched polymers
MY141034A (en) Hydroxybiphenyl carboxylic acids and derivatives, method for producing the same and their use
WO2001019334A3 (en) Pharmaceutical solutions of levosimendan
WO2000047721A3 (en) Methods of inducing insulin positive progenitor cells
EP1561472A4 (en) SOLID PREPARATION
WO2008021999A3 (en) Dermal drops
AP2001002377A0 (en) Substituted phenoxyacetic acids.
WO2006081008A3 (en) Nucleic acids for apoptosis of cancer cells
WO2000015246A3 (en) Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase